Vendor Intelligence Report: ZhuoYan lab

Published 13 Jun 2026. 21-page investigative report on who is behind ZhuoYan lab: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 38 Finnrick lab tests, ZhuoYan lab’s overall pass rate is 68% (26 pass / 12 fail). The result is not a simple bad-vendor story; it is an uneven-catalog story. Retatrutide is the relative bright spot, Tirzepatide is mixed and complicated by overfill events, and Tesamorelin is the clear avoid signal, including a reported no-active-ingredient failure. The ratings also show methodology sensitivity under stricter grading. Most tested vials lacked batch identifiers, weakening recalls and COA matching.

The corporate record is less “lab” than export-trader. A B2B supplier profile identifies the ZhuoYan entity as a Trader, while a separate ChemicalBook profile for an affiliated peptide e-commerce company shares the Zhengzhou address and product focus. The dossier stops short of proving common beneficial ownership, but the overlapping address, product lines and wholesale/consumer storefronts create a materially different picture from a stand-alone laboratory manufacturer.

The digital footprint is young and channel control is loose. The main consumer domain was registered in 2025 and first archived shortly after; a Wukong site-builder fingerprint led investigators to a same-branded plural-domain storefront. Facebook and TikTok sales personas, international phone-number fronts and WhatsApp aliases appear to be vendor-owned funnel assets rather than an external affiliate network. No public Janoshik verification footprint or authoritative channel list surfaced.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 3 tested products
  • Echemi and ChemicalBook profile captures tying the brand to a Zhengzhou trading/export cluster
  • RDAP, Wayback CDX and Wukong-fingerprint evidence for the main domain and plural sister storefront
  • Facebook/TikTok persona and phone-channel analysis covering Yulia, Xanthia and WhatsApp aliases
  • Traceability review of Finnrick vial records, including batch-ID presence and recallability implications
  • Buyer-risk matrix covering product quality, traceability, corporate transparency, operational newness and advance-payment risk

Risk assessment

  • Product-quality failure risk — high: Driven by Tesamorelin (6 tests, 0 pass / 6 fail, 32.66%) and materially mixed Tirzepatide (20 tests, 15 pass / 5 fail, 77.74%); Retatrutide is the relative bright spot.
  • Traceability / recall failure risk — high: Field review of Finnrick product tables found only isolated batch IDs (ZY10; ZY1.14-06); most tested vials lacked batch identifiers, limiting recallability.
  • Corporate-transparency and authenticity-verification risk — high: Echemi lists Zhengzhou Zhuoyan Technology as a Trader while the consumer brand says “lab”; multiple similar domains/personas/numbers surfaced and no official channel list, authorized-reseller list, or signed/verifiable COA system was found.
  • Operational-newness / continuity risk — medium: Main domain was registered 2025-02-11 and first archived 2025-03-24; public footprint is thin and recent.
  • Advance-payment / buyer-protection risk — medium: Echemi profile states 100% TT in advance for the B2B operation; no public buyer-protection mechanism surfaced in the investigation.